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BACKGROUND: Despite the widespread use of neoadjuvant chemotherapy in breast cancer patients, prediction of individual response
to treatment remains an unsolved clinical problem. Particularly, administration of an inefficient chemotherapeutic regimen should be
avoided. Therefore, a better understanding of the molecular mechanisms underlying response to neoadjuvant chemotherapy is of
particular clinical interest. Aim of the present study was to test whether neoadjuvant chemotherapy with epirubicin/docetaxel induces
early changes in the plasma proteome of breast cancer patients and whether such changes correlate with response to therapy.
METHODS: Plasma samples of 25 breast cancer patients obtained before and 24h after initiation of epirubicin/docetaxel-based
neoadjuvant chemotherapy were analysed using two-dimensional differential gel electrophoresis (2D-DIGE). Protein spots found to
be differentially expressed were identified using mass spectrometry and then correlated with the pathological response after six cycles
of therapy. Markers identified in a discovery set of patients (n¼12) were confirmed in an independent validation set (n¼13).
RESULTS: 2D-DIGE revealed 33 protein spots to be differentially expressed in response to chemotherapy, including the complement
factors C1, C3 and C4, inter-a-trypsin inhibitor, a-1-antichymotrypsin and a-2-Heremans-Schmid glycoprotein (AHSG). With respect
to cytokines, only interleukin (IL)-6, IL-10 and soluble intracellular adgesion molecule 3 (sICAM3) were minimally modulated.
Moreover, two protein spots within the complement component C3 significantly correlated with response to therapy.
CONCLUSION: We have identified acute phase proteins and the complement system as part of the early host response to epirubicin/
docetaxel chemotherapy. As complement C3 cleavage correlates with the efficacy of docetaxel/epirubicin-based chemotherapy,
it has the potential as an easily accessible predictive biomarker.
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Neoadjuvant chemotherapy has become the standard treatment for
patients with locally advanced breast cancer or patients with
operable breast cancer in which breast-conserving surgery is not
possible or unlikely to result in a satisfactory cosmetic outcome.
However, the individual response to therapy is widely variable.
Currently, it is not possible to accurately predict the response in an
individual patient. The only response markers available—albeit
with a low accuracy—are low or absent hormone receptor status,
high grade and non-lobular invasive histology (Kaufmann et al,
2007). As a consequence, more accurate and clinically useful
predictors of response for breast cancer patients receiving
neoadjuvant chemotherapy need to be identified.
Ample evidence suggests that the efficacy of chemotherapy is
related both to the molecular profile of the tumour (Potti et al,
2006), as well as the host response to therapy (Zitvogel et al, 2008).
The introduction of profiling technologies has enabled genome- or
proteome-wide searches for predictive and prognostic biomarkers
in pre-therapeutic biopsies of tumour and surrounding host
tissue. However, only a few predictive marker sets have yet been
successfully validated for routine use in the clinic (van de Vijver
et al, 2002; Paik et al, 2004). A significant limitation of the
above approaches is that only a single point in time is taken into
consideration. Thus, dynamic changes during the course of therapy,
which may reflect treatment-associated tumour/host changes
correlating with response to therapy, are not adequately addressed.
Preliminary studies have shown that radio- or chemotherapy-
induced changes of apoptotic pathways can be detected by
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simmunochemistry as early as 48h after initiation of treatment (Stift
et al, 2003) and correlated with therapeutic efficacy (Stearns et al,
2003, p. 23). Further support for this observation comes from a recent
study in patients with rectal cancer who received 5 weeks of
cetuximab-based neoadjuvant therapy (Debucquoy et al, 2009). The
authors analysed the levels of 96 different proteins in plasma samples
taken before and one day after application of the initial chemo-
therapeutic dose. Therapy-induced changes in expression of six
proteins after the initial dose were found to predict the occurrence of
local recurrences and/or distant metastases after the end of therapy.
On the basis of the above results, we hypothesised that the
immediate response of tumour and/or host cells to neoadjuvant
chemotherapy results in distinct early changes of the plasma
protein composition. We also hypothesised that these early ‘host
changes’ may correlate with response to treatment that could allow
for early response prediction using easily accessible predictive
markers: that is, patients who are predicted to be non-responders
to neoadjuvant chemotherapy could either be switched early to
a different, potentially more effective therapeutic regimen or,
alternatively, be scheduled for upfront surgery.
In the present study, we performed serial proteomic analyses
of the plasma protein composition of 25 breast cancer
patients receiving neoadjuvant chemotherapy with epirubicin
and docetaxel. Our results indicate that the initial dose of
epirubicin and docetaxel leads to a significant modulation of the
complement cascade, whereas the cytokine cascade is little
affected. It is important that we were able to identify two comple-
ment isoforms the plasma levels of which correlated with response
to therapy. If validated, our results could form an important basis
for future complement-based response prediction systems in
breast cancer patients receiving neoadjuvant chemotherapy.
MATERIALS AND METHODS
Patient characteristics
Between November 2005 and August 2008, 25 patients with
biopsy-proven early or locally advanced breast cancer who were
suitable for neoadjuvant chemotherapy were enrolled in
this study (for patient characteristics see Table 1). The thera-
peutic regimen consisted of six cycles of neoadjuvant chemo-
therapy with epirubicin and docetaxel (every 3 weeks for a
total duration of 18 weeks) with the addition of granulocyte
colony stimulating factor (G-CSF) support. Blood samples were
taken immediately before (T1) and 24h after the initial dose
of the therapy (T2). For assessment of response to chemo-
therapy, the tumour size upon radiological imaging before
initiation of treatment (S1) was compared with the tumour size
upon pathohistological examination (S2), using the World Health
Organization criteria (Miller et al, 1981). Complete remission was
defined as disappearance of all invasive tumours in the
pathological specimen (‘pathological complete response’). Patients
achieving a complete or partial remission were defined as
responders, whereas patients with stable or progressive disease
were defined as non-responders. The study was approved by the
local ethics committee.
Blood collection and sample preparation
Blood was collected in K3EDTA tubes (Vacutainer, Greiner
Bio-One, Kremsmu ¨nster, Austria) and plasma was prepared
within 60min by centrifugation at 2400g for 15min. The upper
2/3 of the supernatant were taken, immediately shock frozen and
were stored at  801C for 3–16 months. In a pilot experiment with
four parallel gels per group we found no significant difference in
the proteome analysis between samples that were stored for either
6 or 11 months. In addition, the storage time was nearly identical
for samples taken from responders (3–15 months) and non-
responders (5–16 months). The 12 most abundant plasma proteins
(human serum albumin, immunoglobulin (Ig) G, a-1-antitrypsin,
IgA, IgM, transferrin, haptoglobin, a-1-acid glycoprotein, a-2-
macroglobulin, apolipoproteins A-I and A-II and fibrinogen) were
removed from each sample using the ProteomeLab IgY12-LC2
proteome partitioning kit (Beckman Coulter, Fullerton, CA, USA).
The remaining plasma proteins were precipitated using trichloro-
acetic acid as described (Zellner et al, 2005) and resolubilised
Table 1 Patient characteristics
Pat. No. Age Type T-Stage N-Stage ER PR
a HER-2 Grading Response Response group
Discovery set 1 61 Lobular 4b + + +   2S D N R
2 41 Ductal 4b       3P R R
3 52 Ductal 3   +    3 pCR R
4 30 Ductal 3 +    Amplified 2 PR R
5 56 Lobular 3 + +    2P R R
6 74 Lobular 2 + + +   3S D N R
7 51 Ductal 2       3P R R
8 68 Ductal 2       3 pCR R
9 37 Ductal 2       3S D N R
10 46 Lobular 2 + +    3S D N R
11 52 Ductal 2 +      3S D N R
12 60 Ductal 3 + +    1P D N R
Validation set 13 51 Ductal 2       3 PCR R
14 53 Ductal 2 +      3P R R
15 62 Ductal 2   ++   2P R R
16 51 Ductal 2 +      3S D N R
17 48 Ductal 3   + + Amplified 2 PCR R
18 40 Ductal 2 + + +   2S D N R
19 30 Ductal 2       3S D N R
20 59 Lobular 2 + + +   2S D N R
21 66 Ductal 2 +      3P R R
22 58 Lobular 3 + +   Amplified 2 PR R
23 50 Lobular 2 + +    2S D N R
24 52 Ductal 2 + + +   2P D N R
25 38 Ductal 2   ++   3S D N R
Abbreviations: ER¼oestrogen receptor; HER-2¼human epidermal growth factor receptor; pCR¼complete pathological remission; PD¼progressive disease;
NR¼nonresponder; PR¼partial remission; R¼responder; SD¼stable disease.
aProgesterone receptor.
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sin 2D sample buffer containing 7 M urea, 2 M thiourea, 4% 3-((3-
cholamidopropyl)dimethylammonium)-1-propanesulfonate (CHAPS)
and 25mM Tris-HCl (pH 8.5). The protein concentration was
determined using the Coomassie Plus Protein Assay Reagent (Pierce,
Rockford, IL, USA).
Proteomic analysis
Equivalents of 20mg of the two depleted plasma samples per patient
(T1 and T2) were labelled alternating with fluorescent cyanine dye
Cy3 or Cy5 according to the manufacturer’s protocol (GE Healthcare,
Uppsala, Sweden). In addition, a pool of an aliquot of all samples of
all patients was labelled with Cy2 as an internal standard. Two
samples derived from one patient and 20mgo fi n t e r n a ls t a n d a r dw e r e
pooled and filled up with rehydration solution (7 M urea, 2 M thiourea,
4% CHAPS, 70mM dithiothreitol, 1% ampholytes pH 4–7, bromo-
phenol blue) to 450ml each. Isoelectric focusing was carried out on
Ettan IPGphor Isoelectric Focusing Units (GE Healthcare) after
p a s s i v es a m p l er e h y d r a t i o ni n2 4 cm Immobiline DryStrips pH 4-7
(GE Healthcare) until 30kVh were reached. Then strips were
equilibrated for 15min in equilibration solution (6 M urea, 50mM
Tris-HCl (pH 8.8), 30% glycerol, 2% sodium dodecyl sulphate)
containing 10mgml
 1 dithiothreitol (Roche Diagnostics, Mannheim,
Germany) and subsequently for 15min in equilibration solution
containing 25mgml
 1 iodoacetamide (Sigma-Aldrich, St Louis, MO,
USA). Strips were then applied on 9% polyacrylamide gels and
electrophoresis was performed using the Ettan DALT six apparatus
(GE Healthcare). Then gels were scanned as described previously
(Winkler et al, 2008) using the Typhoon TRIO—Variable Mode
Imager (GE Healthcare).
Spots were excised from gels and subjected to in-gel digestion
using trypsin (proteomics grade, Roche Diagnostics). After ZipTip
C18 purification the digest extracts were analysed on a matrix-
assisted laser desorption ionisation time-of-flight mass spectrometer
(CFRplus, Shimadzu Biotech Kratos Analytical, Manchester, UK)
using the thin layer preparation technique (Vorm et al, 1994) with
a-cyano-4-hydroxycinnamic acid (Sigma-Aldrich) as matrix. All mass
spectra were recorded in the positive ion reflectron mode. After
manual peak picking lists of monoisotopic m/z values were submitted
to publically available, web-based versions of peptide mass fingerprint
search engines (MASCOT (Perkins et al,1 9 9 9 ) ) ,A l d e n t ea n d
ProFound (Zhang and Chait, 2000) using the NCBInr database (date:
20090214; taxonomy human: 221591 protein sequences). From the
peptide mass fingerprints selected tryptic peptides were chosen for
post source decay experiments. Protein identification was further
confirmed by submitting m/z values of detected fragment ions to
MASCOT. If post source decay experiments were not successful a
protein was still considered as identified if at least two different
search engines (MASCOT, ProFound or Aldente) listed the same
protein after peptide mass fingerprint search and the protein was
located at a reasonable location on the 2D gels. No special emphasis
was laid on discrimination of protein isoforms.
Western blot
Western blot of 2D gels was performed as described elsewhere
(Zellner et al, 2005). Following primary antibodies were used:
polyclonal chicken anti-human C3 (1:10000) (Lee Biosolutions,
St Lousi, MO, USA), polyclonal goat anti-human C4 (1:10000)
(Lee Biosolutions), murine monoclonal anti-human C4d (1:2000)
(Quidel, San Diego, CA, USA). After washing, membranes were
incubated for 1h at room temperature with the corresponding Cy5
conjugated secondary antibodies (Cy5-conjugated donkey anti-
mouse IgG (Fab fragment; 1:1000) (Jackson ImmunoResearch
Laboratories, Suffolk, UK), Cy5-conjugated rabbit anti-chicken IgY
(1:500) (Biomeda, Foster City, CA, USA), Cy5-conjugated donkey
anti-goat IgG (Fab fragment; 1:500) (Jackson ImmunoResearch
Laboratories) in 2% non-fat dry milk. To match the western blot
images with the two-dimensional differential gel electrophoresis
(2D-DIGE) images the gel image warping software Delta-2D
(Decodon, Greifswald, Germany) was used.
Immunologic analyses
C4d fragment enzyme immunoassay, in which the plasma samples
were diluted 1:40, was performed according to the manufacturer’s
protocol (Quidel). Total levels of complement components C3
and C4 in plasma were determined using the assay kit N Antisera
to Human Complement Factors (C3c, C4) (Dade Behring,
Marburg, Germany), which is based on immunonephelometry.
A Human Th1/Th2 Plex FlowCytomix kit (Bender MedSystems,
Vienna, Austria) was used to quantify the plasma cytokine
levels. The assay was performed according to the manufacturer’s
instructions. Beads were run on a FC500 flow cytometer
(Beckman-Coulter, Miami, FL, USA) for data collection. Further
quantification was performed using the FlowCytomix Pro 2.2
software (Bender MedSystems).
Statistical analysis
Estimation of sample size for proteomic analysis of the discovery
set was based on the results of our previous study on the biological
variation in proteomic samples (Winkler et al, 2008). Using the
same DIGE technology as in the present work to analyse blood
samples from 20 healthy volunteers revealed a median variation s
over all proteins of 18%. In the present study, we monitored only
mean protein expression changes (D) between T1 and T2 of at
least 30%. This consequently corresponds to a minimal effect size
y¼D/s¼0.3/0.18¼1.7. On the basis of this y we calculated the
asymptotic power per hypothesis of the two-sided two-sample
paired Student’s t-test. The error of multiple testing was corrected
using an asymptotic false discovery rate (according to (Benjamini
and Hochberg, 1995)) of 5% targeted at 700 candidate proteins in
which 25 of the proteins were effective. For a sample size of 12 per
group the resulting power was 0.92, which was regarded as
acceptable. In the validation set we were dealing with a much lower
number of parameters (19 C3 and 16 C4 spots) in comparison to
the discovery set (about 700 spots) with nearly the same sample
size (n¼13 vs n¼12). Thus, the problem of multiple testing was
much lower resulting in a considerably higher statistical power.
Quantitation of protein spots was accomplished using the
DeCyder 2D software (version 6.0 from GE Healthcare). Protein
spots outside the molecular weight range of 25–250kDa were
excluded from the analysis. Only protein spots that were found in
at least 9 of 12 gels were included. A total of 688 distinct protein
spots fulfilled these conditions. The paired ratio of the expression
at the time T2 to the expression at T1 was assessed for each spot
and the significance was calculated using a false discovery rate
adjusted paired Student’s t-test as described above.
For determination of the correlation of the effect of the initial dose
with response to chemotherapy, the differences between protein
expression values of time T2 and T1 were assessed for each spot.
Student’s t-test was used to compare these differences (T2–T1)
between non-responders and responders. Differences in total protein
levels of complement components C3, C4 and C4d were calculated
using the paired Student’s t-test. Receiver operating characteristic
(ROC) curves were calculated using the SPSS software (Version 17.0,
IBM Corporation, Armonk, NY, USA).
RESULTS
Impact of neoadjuvant chemotherapy with epirubicin and
docetaxel on plasma proteins
First we investigated whether the initial dose of the neoadjuvant
chemotherapy given for breast cancer affects the plasma proteome
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sat 24h after initiation of therapy as assessed by (2D-DIGE).
Patients receiving an epirubicin and docetaxel combination
therapy in six cycles over 18 weeks were included into the study.
Therefore, samples were taken from 12 patients (¼discovery set)
immediately before they received their initial dose (T1) and the
next day (T2) before G-CSF was given. In total, 688 distinct protein
spots on the 2D gel were analysed quantitatively in each sample.
Expression levels of 33 protein spots were found to be significantly
influenced by the chemotherapeutic initial dose by at least 30%.
Figure 1A indicates their position on a representative 2D gel (see
also Supplementary Data S1). The molecular identity of these spots
has been revealed by mass spectrometry. Table 2 summarises the
results. Acute phase proteins, such as inter-a-trypsin inhibitor,
a-1-antichymotrypsin and a-2-HS glycoprotein, as well as three
different representatives of the complement system (C1r, C3 and
C4), were found to be influenced by the combination therapy. In
addition, an intracellular protein, L-plastin, being upregulated in
response to chemotherapy, was identified (for further details on
the mass spectrometry experiments see Supplementary Data S2).
The 2D-DIGE analysis indicated that chemotherapy influenced the
plasma concentration of these protein species at the level of
different isoforms concomitantly. This supports the relevance of
our findings.
Impact of epirubicin and docetaxel combination therapy
on the plasma cytokine pattern
We further analysed the levels of 17 different cytokines in the plasma
samples, as a number of human and animal data suggest a cytokine
response to chemotherapy. The results are summarised in Table 3
(upper panel). Seven cytokines, including the pro-inflammatory factors
tumour necrosis factor-a,I N F - g and interleukin (IL)-1b, were below the
detection limit before initiation of chemotherapy and remained
undetectable after the initial dose of chemotherapy. The remaining 10
cytokines could be detected at both times. Only three of them showed
significant therapy-induced expression changes: The plasma levels of
pro-inflammatory IL-6, as well as of anti-inflammatory IL-10, were
mildly increased during treatment, whereas the levels of soluble
intracellular adgesion molecule 3 (sICAM3) were mildly decreased.
However, the absolute plasma levels of all measured cytokines were at all
times very low and always in a range observed for healthy volunteers.
Therapy-induced concentration changes of complement
factors C3 and C4
As a major finding of the 2D-DIGE analysis was the modulation
of complement C3 and C4 factors, we next investigated whether
pl 4 pl 7 pl 4 pl 7 pl 4 pl 7
MW
(kDa)
250
150
100
75
50
37
25
Figure 1 Two-dimensional gel electrophoresis of the plasma proteome. (A) Position of protein spots most significantly influenced by the initial dose of
the therapy on a representative 2D-gel image. Their molecular identity is indicated in Table 2. The underlined numbers represent members of the
complement system. (B and C) show 2D-western blot images using antibodies against complement component C3 (B)o rC 4( C). The detail displayed in
the punctured frame shows the signals obtained by incubation with monoclonal anti-C4d antibody. Only this antibody recognised the upper C4 a-chain.
Protein spots indicated in rectangles represent complement isoforms that are significantly differentially influenced by the initial dose between responders and
non-responders.
Table 2 Protein spots most significantly influenced by the initial dose of epirubicin and docetaxel
Spot ID Protein SwissProt ID Regulation
a Function
195 Complement component C3
b P01024 Up Part of the complement system
235, 239, 242, 248, 257, 258 NI Down
388, 393, 397, 405, 406, 407 Inter-a-trypsin inhibitor heavy chain
inter-a-trypsin inhibitor light chain
P19823
P02760
Up Carrier of hyaluronan in serum
536 Complement component C3
c P01024 Up Part of the complement system
561, 562, 576, 577 Complement component C4
c P0C0L4 Up Part of the complement system
696 Complement C1r
c P00736 Up Part of the complement system
929 NI Up
972 L-plastin P13796 Up Actin-binding protein (intracellular protein)
1064, 1075
d a-1-antichymotrypsin
c P01011 Up Physiological function is unclear, can inhibit formation
of active angiotensin-2
1088
d, 1100
d, 1120, 1132
d,
1133
d, 1136
d, 1160
d, 1162
d
a-2-HS-glycoprotein
c P02765 Down Promotes endocytosis and possesses opsonic
properties
1335 NI Up
1340 Complement component C4 P0C0L4 Up Part of the complement system
Abbreviation: NI¼not identified. Note: The paired Student’s t-test was corrected for multiple testing using the false discovery rate algorithm according to Benjamini and
Hochberg (1995).
aAll proteins fulfill the conditions of Po0.05 and minimal mean change in expression level of 30%.
bIdentification only by 2D-western blotting.
cIdentification
was confirmed by 2D-western blotting using specific antibodies.
dThe position on the gel allowed unambigous identification.
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scomplement modulation could also be monitored by standard
assays. In a nephelometric assay for total plasma levels of C3 and
C4, we found that plasma levels of both complement components
showed a significant decrease in response to the initial chemo-
therapeutic dose, suggesting activation of the cascade (Table 3,
lower panel). Therefore, in addition, we determined the amount of
the C4d activation fragment by enzyme-linked immunosorbent
assay. It is surprising that, in the latter assay we found a significant
decrease in C4d fragment in response to chemotherapy. To
validate these results, the complement factors were additionally
analysed in an independent validation set, including 13 patients
(see also Table 1). We observed largely identical absolute plasma
levels, as well as a therapy-induced decrease in C3, C4 and C4d in
the validation set as in the discovery set of patients. This confirms
that the combination therapy influences the complement cascade
within one day.
Response prediction by early changes in plasma levels of
complement factors C3 and C4
Next, we sought to investigate whether the chemotherapy-induced
changes of complement components C3 and C4 can be correlated
with the final response after six cycles of chemotherapy 18 weeks
later. To do so, the patient population was subdivided in
responders and non-responders. Response to chemotherapy was
assessed by comparison of tumour size as assessed by radiological
imaging before therapy (S1) with tumour size upon patho-
histological examination (S2; see also Table 1). The discovery
set contained six responders and six non-responders. The
plasma levels of total C3, as revealed by the routine nephelometric
method, decreased to a similar extent in both responders and
non-responders (by 17mg per 100ml and 19mg per 100ml,
respectively). Similarly, no difference between responders and
non-responders regarding total C4 plasma levels was observed
(4.6mg per 100ml vs 5.5mg per 100ml). The validation set was
composed of six responders and seven non-responders. Here,
again no significant difference was found for total C3 and total C4.
Activation of the complement system leads to proteolytic
cleavage of the complement factors into smaller fragments. Clearly,
measurement of total C3 and C4 levels cannot detect changes in the
ratio between different fragments and isoforms of these factors.
Western blot analysis of 2D-gels revealed that the plasma contains
numerous isoforms of C3 and C4 (Figures 1B and C). The various
spots were found to be ordered into groups on the 2D western blot
membrane. According to their molecular weight and pI-value
we could identify isoform groups belonging to the C3 a-chain
(113kDa), C3 b-chain (71kDa), C4 a-chain (84kDa), C4 b-chain
(72kDa), as well as the C4 g-chain (33kDa). The comparison of the
positions of the chemotherapy-affected complement spots indi-
cated in Figure 1A (underlined numbers) with the position of
the C3 and C4 spots shown in Figures 1B and C suggests that
epirubicin/docetaxel chemotherapy mainly affects the levels of
C3 and C4 groups with a molecular weight above 75kDa. This
includes the a-chains of C3 and of C4, as well as C3 group 1, which
likely represents the non-cleaved full length C3 protein. The b and
g chains, however, remained largely unaffected by chemotherapy.
Next, we investigated whether there is a correlation with the final
response to therapy at the level of single isoforms. Therefore,
we calculated for all individual 19 C3 and 16 C4 spots (with a
molecular weight above 75kDa) the difference in their plasma
levels between T2 and T1 and subdivided the results according to
the response after completion of chemotherapy. First, the
calculations were made for the discovery set. As shown in Table 4,
the chemotherapy-induced changes in plasma levels of four C3
Table 3 Influence of the chemotherapeutic initial dose on cytokines and complement components C3, C4, as well as the activation fragment C4d
Before initial dose After initial dose Paired Student’s t-test
Mean s.d. Units Mean s.d. units P-value
Cytokine panel
Discovery set (n¼12)
TNFa ND pgml
 1 ND pgml
 1 —
TNFb ND pgml
 1 ND pgml
 1 —
IFNg ND pgml
 1 ND pgml
 1 —
IL-1b ND pgml
 1 ND pgml
 1 —
IL-2 27.7 29.4 pgml
 1 24.6 36.4 pgml
 1 0.491
IL-4 ND pgml
 1 ND pgml
 1 —
IL-5 ND pgml
 1 ND pgml
 1 —
IL-6 1.0 0.01 pgml
 1 4.5 1.6 pgml
 1 0.003
IL-8 2.6 17.6 pgml
 1 23.1 30.7 pgml
 1 0.268
IL-10 5.1 1.0 pgml
 1 8.5 3.5 pgml
 1 0.001
IL-12p70 ND pgml
 1 ND pgml
 1 —
sE-selectin 86.7 52.5 ngml
 1 88.8 55.5 ngml
 1 0.179
sICAM-1 453.5 177.4 ngml
 1 413.1 146.8 ngml
 1 0.181
sICAM-3 87.6 23.8 ngml
 1 64.1 20.7 ngml
 1 0.011
sPECAM-1 200.4 93.5 ngml
 1 139.4 61.7 ngml
 1 0.069
sP-selectin 428.5 182.5 ngml
 1 405 130.9 ngml
 1 0.178
sVCAM-1 420.8 622.4 ngml
 1 468.4 259.7 ngml
 1 0.288
Complement factors
Discovery set (n¼12)
C3 144.2 15.40 mg per 100ml 127.9 17.3 mg per 100ml 0.002
C4 30.4 6.00 mg per 100ml 24.5 6.8 mg per 100ml o0.001
C4d 3.6 1.40 mgml
 1 2.6 1.0 mgml
 1 0.007
Validation set (n¼13)
C3 124.6 16.50 mg per 100ml 118.1 19.3 mg per 100ml 0.011
C4 27.0 5.90 mg per 100ml 23.5 5.3 mg per 100ml 0.019
C4d 2.8 1.00 mgml
 1 2.2 0.8 mgml
 1 0.004
Abbreviation: ND¼not detectable.
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sisoforms and three C4 isoforms were found to be significantly
different between responders and non-responders. Specifically, in
the group of non-responders the mean plasma level of the C3
group 1 spot 195 increased by 41.5% after the initial chemotherapy
dose. This increase was significantly stronger in comparison to
the responder group. In contrast, the C3 a1 spot 465 decreased
in the non-responders, whereas it remained nearly unchanged in
the responders. To confirm these data, we performed the same
analysis in the validation set. The initial dose-induced plasma
level changes of the above spots 195 and 529 showed again an
association with the final response to therapy with a P-value
of 0.047 for spot 195 and a borderline significant P-value of 0.054
for spot 529. Calculation of the combined significance for both
the discovery and validation set taken together revealed highly
significant P-values of 0.013 and 0.005, respectively. This strongly
suggests that the immediate response of the plasma levels of these
two C3 isoforms correlates with the final response of the tumour
to chemotherapy.
Spot 529 was clearly assigned to the C3 a–chain, whereas spot
195 likely corresponds to non-cleaved C3. Correspondingly, the
two spots changed contrariwise in response to chemotherapy:
although spot 195 decreased in the group of responders, spot 529
increased (see Table 4). To estimate the predictive value of
these changes, further calculations were made. We calculated the
difference of the treatment-induced expression changes of the two
spots in each patient (529–195). The result was used to calculate a
receiver operating characteristics (ROC) of this score. The analysis
revealed for the discovery set an area under the curve of 0.917
and for the validation set an area under the curve of 0.944. The
area under the curve over all 25 samples was 0.908 (with a standard
error of 0.063 and an asymptotic significance of 0.001). The
529-195 score was able to distinguish between responders and
non-responders with a sensitivity of 0.80 and a specificity of 0.83.
This suggests that the way in which complement factor C3 is
processed in response to the initial dose of epirubicin/docetaxel
combination therapy is indicative for the effect of the therapy on the
tumour and could be useful to predict the outcome of treatment.
DISCUSSION
In the present study we have found that epirubicin/docetaxel
chemotherapy leads to a modulation of the complement cascade,
as well as the acute phase proteins inter-a-trypsin inhibitor,
a-1-antichymotrypsin and a-2-HS glycoprotein. These effects were
observed 24h after the initial dose of therapy allowing for a very
early evaluation of the body’s response to treatment. Time course
experiments revealed that most of these expression changes
remained stable on day 2 and 3, but were undetectable at day 14
(data not shown). The complement system is affected by
epirubicin/docetaxel chemotherapy at the level of different
components of the cascade, as well as at the level of different
isoforms of these components. This corroborates the significance
of the results. It is important that a differential modulation of two
C3 isoforms between responders and non-responders was
observed in a training set of 12 patients which could be confirmed
in an independent validation set of 13 patients. Our data highlight
the role of complement as an important host response factor that
could be used for early identification of non-responders to
neoadjuvant chemotherapy in breast cancer patients.
Despite a growing body of evidence illustrating the complement
system as an important factor in cancer patients, the complement
system has so far achieved little attention in clinical oncology.
Previous proteomic studies found increased levels of different
components of the complement system in sera of patients with
colorectal cancer (Habermann et al, 2006; Ward et al, 2006) and in
plasma of patients with breast cancer (Nakshatri et al, 2009). A
study in patients with pancreatic cancer revealed that preoperative
plasma levels of nine proteins, including complement factors
C1q-B, C3 and C4A correlated with the 1-year disease-free survival
(Lin et al, 2006). Moreover, a panel of five serum proteins,
including complement factor C3a was able to predict the 5-year
metastasis-free survival in breast cancer patients (Goncalves et al,
2006). However, complement component C3a was found to lack
specificity for early diagnosis of breast cancer, limiting its utility as
a stand-alone tumour marker (Li et al, 2005).
Usually, complement is seen as an immunological guardian
against pathogens and damaged cells. In this line complement is
thought to promote antibody-dependent cytotoxicity in the cancer
setting (Macor and Tedesco, 2007). However, recent murine
experiments have also indicated that the activation of C5a, which
is activated by C3, leads to immunosuppression of tumour-
infiltrating monocytes (Markiewski et al, 2008). In this way C5a
promotes murine tumour growth as tumours frequently modulate
host response signals from the microenvironment for their own
advantage. Furthermore, cancer cells have been found to be more
resistant to complement-mediated lysis and they use this attribute
to set up a locally immunosuppressive environment (Loveland and
Cebon, 2008).
In the present study, we describe for the first time a modulation
of the complement cascade by a specific chemotherapy in breast
cancer patients. We demonstrate a reduced level of total C3 and C4
Table 4 Isoforms of complement components C3 and C4 correlating with response to chemotherapy
Discovery set Validation set Overall
Mean change in expression
after initial dose
Mean change in expression
after initial dose D
b
Student’s
t-test
Complement
factor
a spot-ID
non-resp
(n¼6)
Resp
(n¼6) D
a t-test
non-resp
(n¼7)
resp
(n¼6) D
a t-test (n¼25)
C3
Group 1 195 0.415 0.138  0.277 0.045 0.209  0.167  0.376 0.034  0.309 0.013
a1 465  0.110 0.075 0.185 0.049 0.010 0.140 0.130 0.128 0.150 0.026
a2 529  0.067 0.177 0.244 0.001  0.061 0.304 0.365 0.054 0.304 0.005
a2 534 0.018 0.427 0.409 0.040  0.114  0.025 0.089 0.289 0.209 0.070
C4
a1 559  0.056 0.247 0.302 0.028 0.108 0.189 0.081 0.298 0.188 0.037
a1 561 0.118 0.514 0.397 0.027 0.085 0.218 0.133 0.307 0.266 0.053
a2 676  0.048 0.072 0.120 0.026 0.051 0.210 0.159 0.170 0.135 0.066
aAccording to Figure 1: C3 a1¼group 2; C3 a2¼group 3; C4 a1¼group 1; C4 a2¼group 2.
bDifference between non-responder and responder.
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sthat is suggestive of complement activation in response to
chemotherapy, even though we did not find an increase of the
complement activation marker C4d in our samples. We still favour
the interpretation of our data as complement activation, as there is
also evidence for several bypass pathways of complement activation
(Li et al, 2007). Activation might be induced by chemotherapy-
induced apoptosis of tumour cells. Corroboration for this hypo-
thesis comes from the fact that complement factors are involved in
the removal of apoptotic cells. Complement factors C1q, C3 and C4
have been described to bind specifically to apoptotic cells (Paidassi
et al, 2008). Such marked cells are then recognised and eliminated
by macrophages in a process involving C1q binding to cell surface
expressed calreticulin (Vandivier et al,2 0 0 2 ) .C a l r e t i c u l i ni s
normally found in the cytoplasma and appears on the cell surface
in response to different apoptotic stimuli, such as chemotherapeutic
agents (Apetoh et al,2 0 0 7 ) .A p o p t o s i s - i n d u c e dc o m p l e m e n t
activation differs from the classical antibody-induced activation
cascade that could explain the lacking increase in C4d levels. Further
in vitro and in vivo studies will be necessary to prove this
assumption. Recent reports indicated that tumour cells acquire a
resistance to complement-induced cell death by increasing
expression of membrane-bound complement inhibitory proteins
(Gorter and Meri, 1999) and/or soluble inhibitors, such as factor H
(Ajona et al, 2007). This might further explain why complement
differentially contributes to the response to chemotherapy.
Previously, it was shown that part of the cytotoxic effect of
chemotherapy is mediated by the innate immune system, such as
toll-like receptors (Zitvogel et al, 2008). Our data now suggest that
the complement cascade and acute phase proteins may also be
involved in this process. However, in contrast to the substantial
modulation of the complement cascade and selected acute phase
proteins, we found only little modulation of cytokines in the early
phase of chemotherapy in our patients. Most studies in humans
compared the plasma levels before therapy with the ones after its
completion and hence, there are only few data available about the
immediate effect of the administration of the initial dose on
patients. In this study, we found minimal elevation of the
interleukins IL-6, IL-10 and sICAM3 suggesting only a poor
systemic cytokine response in humans. This is in contrast to
several murine experiments where mice treated with etoposide or
cyclophosphamide showed a rapid increase in blood levels of IL-6
that peaked at 3–6h after administration (Elsea et al, 2008).
Similarly, splenocytes collected from mice treated with cytarabine,
cisplatin, etoposide or melphalan displayed an increase in the
synthesis of several cytokines, including tumour necrosis factor-a
within 24h (de Vries and Singer, 2000). This provides further
evidence that the chemotherapy-induced modulation of comple-
ment is not part of a classical inflammatory response, but rather an
atypical stimulation.
Aside from gaining a better understanding of the immunological
consequences of chemotherapy in humans, we identified early
predictive markers that could enable more individualised therapy
in the future. We identified two protein spots of the complement
component C3 that were differentially modulated by epirubicin/
docetaxel-based chemotherapy. Spot 195 is likely to represent
a still non-cleaved full transcript of C3, whereas spot 529 is
an isoform of its proteolytic product C3 a-chain. This further
supports our assumption that epirubicin/docetaxel-based therapy
results in activation of C3. Responders seem to show higher
activation in comparison to non-responders. To date, the isoforms
that we have detected can only be identified by 2D-gel electro-
phoresis, which renders diagnosis for a larger set of patients not
possible yet. The generation of isoform-specific antibodies could
change this technical obstacle. Moreover, analysis of further
complement-specific or -associated markers might improve a
complement-based prediction assay.
It is well established that corticosteroids can affect acute phase
proteins and the complement system. With the exception of only
one patient all received the glucocorticoid dexamethason-21-
dihydrogenphosphate together with epirubicin and docetaxel.
However, in a still ongoing study with colon carcinoma patients
receiving dexamethason-21-dihydrogenphosphate, but combina-
tion with other chemotherapeutics we could not see the same
changes in the plasma proteome (data not shown). Therefore, it is
unlikely that this drug contributes substantially to the effects on
the complement cascade described above.
It is important that our study has followed a new concept in
response prediction as two different points in time were taken into
consideration, allowing for the assessment of dynamic changes
during chemotherapy. Previous efforts to predict chemotherapy
efficiency largely relied on the assessment of predictive markers or
marker sets in pre-treatment biopsies that then formed the basis to
predict treatment outcome. However, assessing dynamic changes
throughout the early course of neoadjuvant chemotherapy could
offer the advantage that the ‘actual’ efficacy of chemotherapy is
monitored in vivo that could provide more reliable predictive
information.
In conclusion, our data suggest a significant role of the comple-
ment cascade and acute phase proteins in the host response to
neoadjuvant chemotherapy with epirubicin and docetaxel in breast
cancer patients. If validated in a larger series of patients, the
complement system might, therefore, serve as an important future
surrogate marker for therapeutic response and allow for early
identification of breast cancer patients who will not profit from
epirubicin/docetaxel-based neoadjuvant chemotherapy.
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